[1] |
Riccabona G, Decristoforo C.
Peptide targeted imaging of cancer[J]. Cancer Biother RadiopharmCancer Biother Radiopharm, 2003, 18(5): 675-687.
doi: 10.1089/108497803770418238
|
[2] |
Said SI, Mutt V.
Polypeptide with broad biological activity: isolation from small intestine[J]. ScienceScience, 1970, 169(951): 1217-1218.
|
[3] |
Onoue S, Matsumoto A, Nagano Y, et al.
Alpha-helical structure in the C-terminus of vasoactive intestinal peptide: functional and structural consequences[J]. Eur J PharmacolEur J Pharmacol, 2004, 485(1-3): 307-316.
doi: 10.1016/j.ejphar.2003.11.046
|
[4] |
Hoare SR.
Mechanisms of peptide and non-peptide ligand binding to Class B G-protein-coupled receptors[J]. Drug Discov TodayDrug Discov Today, 2005, 10(6): 417-427.
doi: 10.1016/S1359-6446(05)03370-2
|
[5] |
Laburthe M, Couvineau A, Marie JC.
VPAC receptors for VIP and PACAP[J]. Receptors ChannelsReceptors Channels, 2002, 8(3-4): 137-153.
doi: 10.3109/10606820213680
|
[6] |
Laburthe M, Couvineau A.
Molecular pharmacology and structure of VPAC Receptor for VIP and PACAP[J]. Regul PeptRegul Pept, 2002, 108(2-3): 165-173.
doi: 10.1016/S0167-0115(02)00099-X
|
[7] |
Bokaei PB, Ma XZ, Byczynski B, et al.
Identification and characterization of five-transmembrane isoforms of human vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors[J]. GenomicsGenomics, 2006, 88(6): 791-800.
doi: 10.1016/j.ygeno.2006.07.008
|
[8] |
Reubi JC.
In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging[J]. J Nucl MedJ Nucl Med, 1995, 36(10): 1846-1853.
|
[9] |
Reubi JC, Läderach U, Waser B, et al.
Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin[J]. Cancer ResCancer Res, 2000, 60(11): 3105-3112.
|
[10] |
Moody TW, Jensen RT.
Breast cancer VPAC1 receptors[J]. Ann N Y Acad SciAnn N Y Acad Sci, 2006, 1070: 436-439.
doi: 10.1196/annals.1317.058
|
[11] |
Virgolini I, Yang Q, Li S, et al.
Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors[J]. Cancer ResCancer Res, 1994, 54(3): 690-700.
|
[12] |
Koch TR, Michener SR, Go VL.
Plasma vasoactive intestinal polypeptide concentration determination in patients with diarrhea[J]. GastroenterologyGastroenterology, 1991, 100(1): 99-106.
doi: 10.1016/0016-5085(91)90588-C
|
[13] |
Hejna M, Hamilton G, Brodowicz T, et al.
Serum levels of vasoactive intestinal peptide(VIP)in patients with adenocarcinomas of the gastrointestinal tract[J]. Anticancer ResAnticancer Res, 2001, 21(2A): 1183-1187.
|
[14] |
Collado B, Carmena MJ, Clemente C, et al.
Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model[J]. PeptidesPeptides, 2007, 28(9): 1896-1901.
doi: 10.1016/j.peptides.2007.04.015
|
[15] |
Valdehita A, Carmena MJ, Collado B, et al.
Vasoactive intestinal peptide(VIP)increases vascular endothelial growth factor(VEGF)expression and secretion in human breast cancer cells[J]. Regul PeptRegul Pept, 2007, 144(1-3): 101-108.
doi: 10.1016/j.regpep.2007.06.006
|
[16] |
ValdehitaA, BajoAM, Fernández-Martínez AB, etal.
Nuclear localization of vasoactive intestinal peptide(VIP)receptors in human breast cancer[J]. PeptidesPeptides, 2010, 31(11): 2035-2045.
doi: 10.1016/j.peptides.2010.07.024
|
[17] |
Virgolini I, Raderer M, Kurtaran A, et al.
Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors[J]. N Engl J MedN Engl J Med, 1994, 331(17): 1116-1121.
doi: 10.1056/NEJM199410273311703
|
[18] |
Raderer M, Kurtaran A, Hejna M, et al.
123I-labelled vasoactive intestinal peptide receptorscintigraphy in patients with colorectal cancer[J]. Br J CancerBr J Cancer, 1998, 78(1): 1-5.
doi: 10.1038/bjc.1998.433
|
[19] |
RadererM, KurtaranA, Yang Q, et al.
Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer[J]. J Nucl MedJ Nucl Med, 1998, 39(9): 1570-1575.
|
[20] |
Pallela VR, Thakur ML, Chakder S, et al.
99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies[J]. J Nucl MedJ Nucl Med, 1999, 40(2): 352-360.
|
[21] |
Rao PS, Thakur ML, Pallela V, et al.
99mTc labeled VIP analog: evaluation for imaging colorectal cancer[J]. Nucl Med BiolNucl Med Biol, 2001, 28(4): 445-450.
doi: 10.1016/S0969-8051(01)00205-0
|
[22] |
Virgolini I, Traub T, Ofluoglu S, et al.
Human biodistribution, safety and absorbed dose of 99mTc-P1666 vasoactive intestinal peptide(VIP)receptor scintigraphy[J]. J Nucl MedJ Nucl Med, 1999, 40: 244(abstract)-.
|
[23] |
Thakur ML, Marcus CS, Saeed S, et al.
Imaging tumors in humans with Tc-99m-VIP[J]. Ann N Y Acad SciAnn N Y Acad Sci, 2000, 921: 37-44.
|
[24] |
Kothari K, Prasad S, Korde A, et al.
99mTc(CO)3-VIP analogues: preparation and evaluation as tumor imaging agent[J]. Appl Radiat IsotAppl Radiat Isot, 2007, 65(4): 382-386.
doi: 10.1016/j.apradiso.2006.11.001
|
[25] |
Moody TW, Leyton J, Unsworth E, et al.
(Arg15, Arg21)VIP: evaluation of biological activity and localization to breast cancer tumors[J]. PeptidesPeptides, 1998, 19(3): 585-592.
doi: 10.1016/S0196-9781(97)00459-2
|
[26] |
Cheng DF, Yin DZ, Zhang L, et al.
Preparation of the novel fluorine-18-labeled VIP analog for PET imaging studies using two different synthesis methods[J]. J Fluorine ChemJ Fluorine Chem, 2007, 128(3): 196-201.
doi: 10.1016/j.jfluchem.2006.12.007
|
[27] |
Zhang K, Aruva MR, Shanthly N, et al.
Vasoactive intestinal peptide(VIP)and pituitary adenylate cyclase activating peptide(PACAP)receptorspecific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation[J]. Regul PeptRegul Pept, 2007, 144(1-3): 91-100.
doi: 10.1016/j.regpep.2007.06.008
|
[28] |
Zhang K, Aruva MR, Shanthly N, et al.
PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer[J]. J Nucl MedJ Nucl Med, 2008, 49(1): 112-121.
doi: 10.2967/jnumed.107.043703
|
[29] |
Moody TW, Zia F, Draoui M, et al.
A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth[J]. Proc Natl Acad Sci U S AProc Natl Acad Sci U S A, 1993, 90(10): 4345-4349.
doi: 10.1073/pnas.90.10.4345
|
[30] |
Moody TW, Jensen RT, Fridkin M, et al.
(N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist[J]. J Mol NeurosciJ Mol Neurosci, 2002, 18(1-2): 29-35.
doi: 10.1385/JMN:18:1-2:29
|
[31] |
Moody TW, Czerwinski G, Tarasova NI, et al.
VIP-ellipticine derivatives inhibit the growth of breast cancer cells[J]. Life SciLife Sci, 2002, 71(9): 1005-1014.
doi: 10.1016/S0024-3205(02)01741-1
|
[32] |
Moody TW, Czerwinski G, Tarasova NI, et al.
The development of VIP-ellipticine conjugates[J]. Regul PeptRegul Pept, 2004, 123(1-3): 187-192.
doi: 10.1016/j.regpep.2004.03.021
|
[33] |
Moody TW, Mantey SA, Fuselier JA, et al.
Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells[J]. PeptidesPeptides, 2007, 28(9): 1883-1890.
doi: 10.1016/j.peptides.2007.04.017
|